Eloralintide for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 15 Dec 2025: Trial registered, NCT07282600
  2. 15 Dec 2025: Trial started, NCT07282600

The trials

NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

State
Completed
Phase
Phase 2
People
367 taking part
Started
20 Sep 2024
Primary completion
1 Jul 2026
Arms
LY3841136 Dose 1, LY3841136 Dose 2, LY3841136 Dose 3, LY3841136 Dose 1 + Tirzepatide Dose 1, LY3841136 Dose 2 + Tirzepatide Dose 1, LY3841136 Dose 2 + Tirzepatide Dose 2, LY3841136 Dose 3 + Tirzepatide Dose 3, LY3841136 Dose 2 + Tirzepatide Dose 3
Results
None posted
  1. 19 Sep 2024: Trial registered
  2. 20 Sep 2024: Trial started
  3. 14 Sep 2026: Trial completed

NCT07215559: A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

State
Under way
Phase
Phase 2
People
200 planned
Started
16 Oct 2025
Primary completion
Mar 2027
Arms
Eloralintide (Elorlintide + Macupatide Placebo)
Results
None posted
  1. 10 Oct 2025: Trial registered
  2. 16 Oct 2025: Trial started

NCT07282600: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

State
Under way
Phase
Phase 3
People
1,035 planned
Started
15 Dec 2025
Primary completion
Jan 2028
Arms
Eloralintide Dose 1, Eloralintide Dose 2, Eloralintide Dose 3, Eloralintide Dose 4
Results
None posted
  1. 15 Dec 2025: Trial registered
  2. 15 Dec 2025: Trial started

NCT07900633: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

State
Not started
Phase
Phase 3
People
3,000 planned
Started
Dec 2026
Primary completion
Nov 2029
Arms
Eloralintide
Results
None posted
  1. 28 Oct 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.